MARKET

QNRX

QNRX

Quoin Pharmaceuticals Ltd
NASDAQ
2.480
+0.190
+8.30%
After Hours: 2.500 +0.02 +0.81% 19:56 10/04 EDT
OPEN
2.336
PREV CLOSE
2.290
HIGH
2.520
LOW
2.300
VOLUME
239.26K
TURNOVER
0
52 WEEK HIGH
237.24
52 WEEK LOW
2.211
MARKET CAP
11.90M
P/E (TTM)
-0.0004
1D
5D
1M
3M
1Y
5Y
BRIEF-Quoin Pharmaceuticals Establishes Patient Specific Website For Ongoing Netherton Syndrome Clinical Study
BRIEF-Quoin Pharmaceuticals Establishes Patient Specific Website For Ongoing Netherton Syndrome Clinical Study
Reuters · 09/13 14:33
Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
Gainers
Benzinga · 09/08 09:26
Why Korn Ferry Is Trading Lower By Over 8%, Here Are 40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 64% to $0.1199. Allena Pharmaceuticals shares dipped over 30% on Tuesday after the company announced it has filed for bankruptcy.
Benzinga · 09/07 16:22
Nasdaq Surges 100 Points; Crude Oil Falls Sharply
U.S. stocks traded higher this morning, with the Nasdaq Composite adding more than 100 points on Wednesday.
Benzinga · 09/07 16:09
US Stocks Edge Higher; Dow Rises 50 Points
U.S. stocks traded slightly this morning, with the Dow Jones adding more than 50 points on Wednesday.
Benzinga · 09/07 14:24
ATHX, VSTM and TUP are among pre market gainers
IMARA (IMRA) +41%. BioVie (<a href="https://seekingalpha.com/symbol/BIVI?utm...
Seekingalpha · 09/07 12:23
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 09/07 12:21
Alliance Global Partners Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20
Alliance Global Partners analyst James Molloy initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $20.
Benzinga · 09/07 11:59
More
About QNRX
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Webull offers kinds of Quoin Pharmaceuticals Ltd - ADR stock information, including NASDAQ:QNRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QNRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QNRX stock methods without spending real money on the virtual paper trading platform.